Health Sector Innovations: From Blood Thinners to Bird Flu Outbreaks
Recent health news highlights clopidogrel's superiority over aspirin for heart conditions, a $2 billion neuromuscular therapy deal, and Gilead's new manufacturing hub. Zymeworks halts a cancer drug trial, Pfizer defends its COVID vaccine, while Portugal and Germany face bird flu outbreaks. Aspen aims for profit through insulin drugs.
Health news recently focused on the effectiveness of clopidogrel over aspirin for heart patients, as reported at a European cardiology congress. The study on 29,000 patients revealed clopidogrel's 14% better efficacy in reducing heart risks.
Arrowhead Pharmaceuticals announced a $2 billion neuromuscular therapy deal with Novartis. Meanwhile, Gilead is investing $32 billion in a new manufacturing hub in California to enhance domestic production amidst tariff concerns.
While Zymeworks ceased a cancer drug trial, Pfizer defended its COVID vaccine following Trump's remarks. Additionally, bird flu outbreaks were reported in Portugal and Germany. Aspen seeks profit growth through insulin and GLP-1 drugs.
(With inputs from agencies.)
Advertisement
Google News